BiotechTube
CelLBxHealth

CelLBxHealth

London, United Kingdom· Est.
cellbxhealth.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CelLBxHealth is a publicly traded, commercial-stage diagnostics company leveraging its proprietary Parsortix microfluidics platform to isolate intact circulating tumor cells from a simple blood draw. Its core business involves selling the Parsortix PC1 system (clinical) and PR1 system (research), complemented by a global GCP-compliant laboratory service offering for pharma and research clients. The company is positioned in the high-growth liquid biopsy market, aiming to enable minimally invasive, repeatable testing for cancer monitoring and research across multiple solid tumor types.

Oncology

Technology Platform

Parsortix® platform: an epitope-independent, microfluidic system that captures circulating tumor cells (CTCs) from whole blood based on size and deformability, yielding intact cells for downstream molecular analysis.

Opportunities

The growing liquid biopsy market, particularly for therapy monitoring and biomarker discovery in pharma trials, presents a major opportunity.
The company's unique epitope-independent CTC capture technology addresses a gap in capturing a broader range of tumor cells, which could become a key differentiator in research and clinical settings.

Risk Factors

Intense competition from both other CTC platforms and dominant cfDNA liquid biopsy methods poses a market adoption risk.
Achieving widespread clinical reimbursement for tests using its platform remains a significant financial and regulatory hurdle that could limit growth.

Competitive Landscape

CelLBxHealth competes in the CTC capture segment against companies like Menarini Silicon Biosystems (CellSearch) and other microfluidic platform developers. Broader competition includes the entire liquid biopsy market, dominated by large players like Guardant Health and FOUNDATION Medicine focused on cfDNA. Its key competitive edge is its label-free, epitope-independent capture method.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →